期刊文献+

匹维溴铵联合依帕司他甲钴胺治疗糖尿病性肠病的临床研究 被引量:6

Clinical Study on Diabetic Intestinal Disease Treated by Pinaverium Bromide Combined with Epalrestat and Methylcobalamin
下载PDF
导出
摘要 目的:探讨匹维溴铵联合依帕司他、甲钴胺治疗糖尿病性肠病的疗效及可行机制。方法:选择在廊坊市人民医院门诊及住院治疗的2型糖尿病并发糖尿病性肠病的患者208例,将208例符合上述标准的门诊及住院患者分成两组,观察组及治疗组各104例,两组患者均给予胰岛素控制血糖,观察前停用影响胃肠道动力的药物。观察组加用甲钴胺0.5微克3/d口服;治疗组在原有甲钴胺0.5微克3/d口服的基础上,联合匹维溴铵50mg 3/d及依帕司他50mg3/d口服治疗,连续服用3个月。结果:两组患者临床资料的对比差异不具有统计学意义(P>0.05)。两组患者疗效对比,治疗组总有效率明显高于观察组,差异具有统计学意义(P<0.05)。两组患者治疗后腹泻情况及便秘情况得分对比,治疗组治疗后的得分明显低于观察组治疗后得分,差异具有统计学意义(P<0.05)。结论:匹维溴铵联合依帕司他、甲钴胺治疗糖尿病性肠病疗效显著,值得推广应用。 Objective:To investigate the efficacy and feasible mechanism of pinaverium bromide combined with epalrestat and mecobalamin in the treatment of diabetic bowel disease.Methods:A total of 208 patients with type 2 diabetes mellitus complicated with diabetic bowel disease were selected in outpatient and inpatient treatment in Langfang People’s Hospital.208 outpatients and inpatients meeting the above criteria were randomly divided into two groups.Each group received 104 patients in the treatment group.In both groups,insulin was administered to control blood glucose,and drugs that affect gastrointestinal motility were discontinued before observation.The observation group was treated with methylcobalamin 0.5μg 3/day orally;the treatment group was on the basis of 0.5μg of original mecobalamin 3/day orally,combined with pinaverium bromide 50 mg 3/day and epalrestat 50 mg 3/Oral treatment daily for 3 months.Results:There was no significant difference in clinical data between the two groups(P>0.05).The efficacy of the two groups was significantly higher than that of the observation group.The difference was statistically significant(P<0.05).The scores of diarrhea and constipation and after treatment were compared between the two groups.The scores after treatment in the treatment group were significantly lower than those in the observation group after treatment.The differences were statistically significant.Significance(P<0.05).Conclusion:Pinaverium bromide combined with Epalrestat and Methylcobalamin have significant curative effects on diabetic bowel disease,which is worthy of popularization and application.
作者 杨俐 辛薇 崔硕 王迪 郭莹辉 杨志霞 YANG Li;XIN Wei;CUI Shuo(Langfang People's Hospital,Hebe Langfang 065000,China)
出处 《河北医学》 CAS 2019年第9期1532-1535,共4页 Hebei Medicine
基金 河北省自然科学基金资助项目,(编号:H2014206177) 河北省廊坊市科技支撑计划项目,(编号:2017013139)
关键词 糖尿病性肠病 匹维溴铵 依帕司他 甲钴胺 Diabetic bowel disease Pinaverium bromide Epalrestat Methylcobalamin
  • 相关文献

参考文献7

二级参考文献67

  • 1中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中国肝脏病杂志(电子版),2010,2(4):43-48. 被引量:469
  • 2刘新光.肠易激综合征与罗马Ⅲ诊断标准[J].胃肠病学,2006,11(12):736-738. 被引量:279
  • 3陈朝元,王岩,林琼,何顺勇.难治性肠易激综合征患者精神心理因素分析[J].临床心身疾病杂志,2007,13(6):525-526. 被引量:16
  • 4Boland BS, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes[J]. Endocrinol Metab Clin North Am,2013,42(4) :809--832.
  • 5Thazhath SS, Jones KL, Horowitz M, et al. Diabetic gastroparesis: recent insights into pathophysiology and implications for management[J]. Expert Rev Gastroenterol Hepatol, 2013,7(2) : 127--139.
  • 6Shin AS, Camilleri M. Diagnostic assessment of diabetic gastroparesis[J]. Diabetes,2013,62(8) :2667--2673.
  • 7Satirapoj B. Nephropathy in diabetes[J]. Adv Exp Med Biol, 2012,771(3) :107--122.
  • 8Negishi K,Seicean S,Negishi T, et al. Relation of heart-rate recovery to new onset heart failure and atrial fibrillation in patients with diabetes mellitus and preserved ejection fraction [J]. Am J Cardiol,2013,111(5) :748 --753.
  • 9Deli G, Bosnyak E, Pusch G, et al. Diabetic neuropathies: diagnosis and management[J]. Neuroendoerinology, 2013,98 (4) ,267--280.
  • 10Arezzo JC. New developments in the diagnosis of diabetic neuropathy [J]. Am J Med,1999,107(2B) :9.

共引文献57

同被引文献73

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部